GRAIL Will Be Listed And Commence Regular-Way Trading On The Nasdaq Under The Symbol "GRAL" As Of June 25, 2024.
GRAIL Will Be Listed And Commence Regular-Way Trading On The Nasdaq Under The Symbol "GRAL" As Of June 25, 2024.
2024年6月25日,格雷爾將在納斯達克上市,並在標的爲“GRAL”的常規交易下開始交易。
Regular Way Trading on Nasdaq Global Select Market to Begin Tomorrow, June 25
納斯達克全球精選市場上的“定期交易”將於明天,即6月25日開始。
GRAIL is Building and Scaling a Groundbreaking New Cancer Screening Technology
GRAIL正在建立和擴展一種突破性的新型癌症篩查技術。
GRAIL, Inc. (NASDAQ:GRAL, formerly GRAIL, LLC))))), a healthcare company whose mission is to detect cancer early when it can be cured, today announced its spin-off from Illumina (NASDAQ:ILMN) is complete, and GRAIL will be listed and commence regular-way trading on the Nasdaq under the symbol "GRAL" as of tomorrow, June 25, 2024.
醫療保健公司GRAIL(納斯達克股票代碼:GRAL,原名GRAIL,LLC),其使命是在癌症能夠治癒時早期檢測癌症,今天宣佈其與Illumina(納斯達克股票代碼:illumina)分拆完成,並將於明天6月25日在納斯達克上市,標的爲“GRAL”。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。